JP2020516289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516289A5 JP2020516289A5 JP2019555834A JP2019555834A JP2020516289A5 JP 2020516289 A5 JP2020516289 A5 JP 2020516289A5 JP 2019555834 A JP2019555834 A JP 2019555834A JP 2019555834 A JP2019555834 A JP 2019555834A JP 2020516289 A5 JP2020516289 A5 JP 2020516289A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- risk allele
- linkage disequilibrium
- subject
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023121229A JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485077P | 2017-04-13 | 2017-04-13 | |
| US62/485,077 | 2017-04-13 | ||
| PCT/US2018/023266 WO2018190990A1 (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023121229A Division JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516289A JP2020516289A (ja) | 2020-06-11 |
| JP2020516289A5 true JP2020516289A5 (cg-RX-API-DMAC7.html) | 2021-04-22 |
| JP7321939B2 JP7321939B2 (ja) | 2023-08-07 |
Family
ID=61911717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555834A Active JP7321939B2 (ja) | 2017-04-13 | 2018-03-20 | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2023121229A Active JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A Pending JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023121229A Active JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A Pending JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11708415B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3957752B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7321939B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102751957B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN110431240B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2018252974B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059350A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3052989T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL314591B1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019012171A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909457XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018190990A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| MX2019012171A (es) * | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| JP7165618B2 (ja) * | 2019-04-23 | 2022-11-04 | ジェネシスヘルスケア株式会社 | アレルギー性鼻炎のリスクを判定する方法 |
| MX2021013427A (es) * | 2019-05-01 | 2022-01-31 | Sanofi Biotechnology | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. |
| KR20220034878A (ko) | 2019-07-16 | 2022-03-18 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| EP4430211A1 (en) * | 2021-11-11 | 2024-09-18 | Regeneron Pharmaceuticals, Inc. | Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33) |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| PT2990420T (pt) | 2000-05-26 | 2017-03-16 | Immunex Corp | Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos |
| UA93653C2 (ru) | 2003-11-07 | 2011-03-10 | Иммунекс Корпорейшн | Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r) |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CN101426518A (zh) * | 2006-01-11 | 2009-05-06 | 艾罗文斯公司 | 用于治疗人类和非-人类灵长类中哮喘的方法和组合物 |
| FR2900817B1 (fr) * | 2006-05-12 | 2008-12-19 | Gambro Lundia Ab | Bandage a usage medical pour un tube implante dans un patient, ainsi que le procede d'application de ce bandage sur la peau d'un patient |
| CN1896275B (zh) * | 2006-06-29 | 2010-04-07 | 四川大学华西医院 | 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101600456A (zh) * | 2006-12-11 | 2009-12-09 | 惠氏公司 | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| WO2010067381A1 (en) * | 2008-12-12 | 2010-06-17 | Decode Genetics Ehf | Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| ES2549637T3 (es) | 2011-02-23 | 2015-10-30 | F. Hoffmann-La Roche Ag | Anticuerpos contra IL33R humano y la utilización de los mismos |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| KR102502640B1 (ko) * | 2012-08-21 | 2023-02-23 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
| US10703799B2 (en) * | 2012-12-10 | 2020-07-07 | Vib Vzw | IL-33R and IL-1RAcP fusion proteins |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| JP6404314B2 (ja) | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−33拮抗薬とその使用法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
| HUE064292T2 (hu) | 2013-12-26 | 2024-03-28 | Mitsubishi Tanabe Pharma Corp | Humán anti-IL-33 semlegesítõ monoklonális antitest |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| EP3129497B1 (en) * | 2014-04-11 | 2021-09-08 | Novartis AG | Methods of selectively treating asthma using il-13 antagonists |
| NO2785538T3 (cg-RX-API-DMAC7.html) | 2014-05-07 | 2018-08-04 | ||
| JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | 抗インターロイキン−33抗体及びその使用 |
| US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| CN104531689A (zh) * | 2014-12-12 | 2015-04-22 | 上海交通大学医学院附属新华医院 | 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用 |
| MX387295B (es) | 2015-03-31 | 2025-03-18 | Medimmune Ltd | Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos. |
| JP6858182B2 (ja) * | 2015-10-06 | 2021-04-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用 |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| MX2019012171A (es) * | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
-
2018
- 2018-03-20 MX MX2019012171A patent/MX2019012171A/es unknown
- 2018-03-20 CA CA3059350A patent/CA3059350A1/en active Pending
- 2018-03-20 EP EP21162316.0A patent/EP3957752B1/en active Active
- 2018-03-20 WO PCT/US2018/023266 patent/WO2018190990A1/en not_active Ceased
- 2018-03-20 EP EP18716446.2A patent/EP3610041A1/en not_active Withdrawn
- 2018-03-20 IL IL314591A patent/IL314591B1/en unknown
- 2018-03-20 ES ES21162316T patent/ES3052989T3/es active Active
- 2018-03-20 EP EP25162154.6A patent/EP4549586A3/en active Pending
- 2018-03-20 CN CN201880018649.2A patent/CN110431240B/zh active Active
- 2018-03-20 SG SG11201909457X patent/SG11201909457XA/en unknown
- 2018-03-20 IL IL269873A patent/IL269873B2/en unknown
- 2018-03-20 IL IL327281A patent/IL327281A/en unknown
- 2018-03-20 KR KR1020237039438A patent/KR102751957B1/ko active Active
- 2018-03-20 JP JP2019555834A patent/JP7321939B2/ja active Active
- 2018-03-20 CN CN202610146824.2A patent/CN121951033A/zh active Pending
- 2018-03-20 KR KR1020197030870A patent/KR102605045B1/ko active Active
- 2018-03-20 AU AU2018252974A patent/AU2018252974B2/en active Active
-
2019
- 2019-10-10 MX MX2024002689A patent/MX2024002689A/es unknown
- 2019-10-11 US US16/599,709 patent/US11708415B2/en active Active
-
2023
- 2023-06-07 US US18/330,736 patent/US12612462B2/en active Active
- 2023-07-26 JP JP2023121229A patent/JP7557581B2/ja active Active
-
2024
- 2024-09-13 JP JP2024158740A patent/JP2024163308A/ja active Pending
- 2024-09-30 AU AU2024220214A patent/AU2024220214B2/en active Active
- 2024-09-30 AU AU2024220212A patent/AU2024220212B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rutgeerts et al. | A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis | |
| US11016099B2 (en) | Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers | |
| Peyrin-Biroulet et al. | Early Crohn disease: a proposed definition for use in disease-modification trials | |
| JP6563976B2 (ja) | 可溶性ヒトst−2抗体およびアッセイ法 | |
| JP6755240B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法 | |
| JP2013500941A5 (cg-RX-API-DMAC7.html) | ||
| JP2016511823A5 (cg-RX-API-DMAC7.html) | ||
| US11124835B2 (en) | Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers | |
| FI3774897T3 (fi) | Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon | |
| JP2018535394A5 (cg-RX-API-DMAC7.html) | ||
| Gaber et al. | Clinical significance of serum interleukin-6 and− 174 G/C promoter polymorphism in Rheumatoid arthritis patients | |
| JP2011184466A5 (cg-RX-API-DMAC7.html) | ||
| Lucendo | Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies | |
| JP2015501297A5 (ja) | 医薬組成物、方法、診断キット | |
| US10604806B2 (en) | Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers | |
| JP7321939B2 (ja) | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 | |
| Farrokhi et al. | Mannose-binding lectin mediated complement pathway in autoimmune neurological disorders | |
| Pandit et al. | Multisystem inflammatory syndrome in children during the COVID-19 pandemic: A review of clinical manifestations, Cardiac Complications and Medical Management | |
| Sowho et al. | Association of sleep apnoea risk and aortic enlargement in Marfan syndrome | |
| Sahoo et al. | Paradigm of immune dysregulation in coronavirus disease-2019 infection | |
| Cabral-Marques et al. | The relationship between autoantibodies targeting GPCRs and the renin-angiotensin system associates with COVID-19 severity | |
| Carlstrom et al. | Severe asthma: what makes it so hard to manage? | |
| Sarkar et al. | The Role of Anti-inflammatory Agents in the Management of COVID-19 | |
| DINACHE et al. | Rheumatoid Arthritis-Associated Interstitial Lung Disease | |
| JP2016520563A5 (cg-RX-API-DMAC7.html) |